Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome

Neurobiology of Aging

Volumn 33, Issue 9, 2012, Pages 1988-1994

  Coppus, Antonia M W ^a,b   Schuur, Maaike ^b   Vergeer, Jeanet ^b   Janssens, A Cecile J W ^b   Oostra, Ben A ^b   Verbeek, Marcel M ^c   van Duijn, Cornelia M ^b  

^a Dichterbij   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY   (Netherlands)

Author keywords

Abeta; Alzheimer's disease; Amyloid precursor protein; Down syndrome

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER;

ADULT; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CAUSE OF DEATH; CLINICAL EVALUATION; CONTROLLED STUDY; DISABILITY SEVERITY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN SYNDROME; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COMMUNITY HEALTH PLANNING; DISABILITY EVALUATION; DOWN SYNDROME; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; NETHERLANDS; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84863487378     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.08.007     Document Type: Article

References (38)

1. Aylward E.H., Burt D.B., Thorpe L.U., Lai F., Dalton A. Diagnosis of dementia in individuals with intellectual disability. J. Intellect. Disabil. Res 1997, 41:152-164.
2. Cavani S., Tamaoka A., Moretti A., Marinelli L., Angelini G., Di Stefano S., Piombo G., Cazzulo V., Matsuno S., Shoji S., Furiya Y., Zaccheo D., Dagna-Bricarelli F., Tabaton M., Mori H. Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome. Am. J. Med. Genet 2000, 95:224-228.
3. Coppus A., Evenhuis H., Verberne G.J., Visser F., van Gool P., Eikelenboom P., van Duijin C. Dementia and mortality in persons with Down's syndrome. J. Intellect. Disabil. Res 2006, 50:768-777.
4. Coppus A.M., Evenhuis H.M., Verberne G.J., Visser F.E., Arias-Vasquez A., Sayed-Tabatabaei F.A., Vergeer-Drop J., Eikelenboom P., van Gool W.A., van Duijn C.M. The impact of apolipoprotein E on dementia in persons with Down's syndrome. Neurobiol. Aging 2008, 29:828-835.
5. Cosentino S.A., Stern Y., Sokolov E., Scarmeas N., Manly J.J., Tang M.X., Schupf N., Mayeux R.P. Plasma β-amyloid and cognitive decline. Arch. Neurol 2010, 67:1485-1490.
6. Evenhuis H.M. Evaluation of a screening instrument for dementia in ageing mentally retarded persons. J. Intellect. Disabil. Res 1992, 36:337-347.
7. Evenhuis H.M. Further evaluation of the Dementia Questionnaire for Persons with Mental Retardation (DMR). J. Intellect. Disabil. Res 1996, 40:369-373.
8. Graff-Radford N.R., Crook J.E., Lucas J., Boeve B.F., Knopman D.S., Ivnik R.J., Smith G.E., Younkin L.H., Petersen R.C., Younkin S.G. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol 2007, 64:354-362.
9. Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., Blennow K. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord 2007, 23:316-320.
10. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5:228-234.
11. Hansson O., Zetterberg H., Vanmechelen E., Vanderstichele H., Andreasson U., Londos E., Wallin A., Minthon L., Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol. Aging 2010, 31:357-367.
12. Head E., Doran E., Nistor M., Hill M., Schmitt F.A., Haier R.J., Lott I.T. Plasma Amyloid-beta as a Function of Age, Level of Intellectual Disability, and Presence of Dementia in Down Syndrome. J. Alzheimers Dis 2010, 23:399-409.
13. Jones E.L., Hanney M., Francis P.T., Ballard C.G. Amyloid beta concentrations in older people with Down syndrome and dementia. Neurosci. Lett 2009, 451:162-164.
14. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci 2001, 21:372-381.
15. Kosaka T., Imagawa M., Seki K., Arai H., Sasaki H., Tsuji S., Asami-Odaka A., Fukushima T., Imai K., Iwatsubo T. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology 1997, 48:741-745.
16. Krayer D.W., de Bildt A.A. 2004, K., G.N., SRZ/SRZ1, Sociale Redzaamheidsschalen, Handleiding Harcourt Test Publishers.
17. Kupsch A., Sautter J., Götz M.E., Breithaupt W., Schwarz J., Youdim M.B., Riederer P., Gerlach M., Oertel W.H. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm 2001, 108:985-1009.
18. Lambert J.C., Schraen-Maschke S., Richard F., Fievet N., Rouaud O., Berr C., Dartigues J.F., Tzourio C., Alpérovitch A., Buée L., Amouyel P. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 2009, 73:847-853.
19. Matsuoka Y., Andrews H.F., Becker A.G., Gray A.J., Mehta P.D., Sano M.C., Dalton A.J., Aisen P.S. The relationship of plasma Abeta levels to dementia in aging individuals with down syndrome. Alzheimer Dis. Assoc. Disord 2009, 23:315-318.
20. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., Mehta P.D. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003, 61:1185-1190.
21. Mehta P.D., Capone G., Jewell A., Freedland R.L. Increased amyloid beta protein levels in children and adolescents with Down syndrome. J. Neurol. Sci 2007, 254:22-27.
22. Mehta P.D., Mehta S.P., Fedor B., Patrick B.A., Emmerling M., Dalton A.J. Plasma amyloid beta protein 1-42 levels are increased in old Down Syndrome but not in young Down Syndrome. Neurosci. Lett 2003, 342:155-158.
23. Mehta P.D., Pirttila T., Patrick B.A., Barshatzky M., Mehta S.P. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett 2001, 304:102-106.
24. Netzer W.J., Powell C., Nong Y., Blundell J., Wong L., Duff K., Flajolet M., Greengard P. Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS One 2010, 5:e10943.
25. Okereke O.I., Xia W., Selkoe D.J., Grodstein F. Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch. Neurol 2009, 66:1247-1253.
26. Prasher V.P., Sajith S.G., Mehta P., Zigman W.B., Schupf N. Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome. Int. J. Geriatr. Psychiatry 2010, 25:202-207.
27. Reisberg B., Ferris S.H., de Leon M.J., Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am. J. Psychiatry 1982, 139:1136-1139.
28. Roizen N.J., Patterson D. Down's syndrome. Lancet 2003, 361:1281-1289.
29. Schupf N., Patel B., Pang D., Zigman W.B., Silverman W., Mehta P.D., Mayeux R. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch. Neurol 2007, 64:1007-1013.
30. Schupf N., Patel B., Silverman W., Zigman W.B., Zhong N., Tycko B., Mehta P.D., Mayeux R. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci. Lett 2001, 301:199-203.
31. Schupf N., Sergievsky G.H. Genetic and host factors for dementia in Down's syndrome. Br. J. Psychiatry 2002, 180:405-410.
32. Schupf N., Zigman W.B., Tang M.X., Pang D., Mayeux R., Mehta P., Silverman W. Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome. Neurology 2010, 75:1639-1644.
33. Selkoe D.J. Normal and abnormal biology of the beta-amyloid precursor protein. Annu. Rev. Neurosci 1994, 17:489-517.
34. Sundelöf J., Giedraitis V., Irizarry M.C., Sundström J., Ingelsson E., Rönnemaa E., Arnlöv J., Gunnarsson M.D., Hyman B.T., Basun H., Ingelsson M., Lannfelt L., Kilander L. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch. Neurol 2008, 65:256-263.
35. Tokuda T., Fukushima T., Ikeda S., Sekijima Y., Shoji S., Yanagisawa N., Tamaoka A. Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome. Ann. Neurol 1997, 41:271-273.
36. van Oijen M., Hofman A., Soares H.D., Koudstaal P.J., Breteler M.M. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006, 5:655-660.
37. Wisniewski K.E., Dalton A.J., McLachlan C., Wen G.Y., Wisniewski H.M. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 1985, 35:957-961.
38. ICD-10: International Statistical Classification of Diseases and Related Health Problems 1992, World Health Organization, World Health Organization, Geneva. tenth rev.